Vertex Pharmaceuticals Incorporated has announced a revenue of $3.08 billion for the past year, reflecting an 11% increase year-on-year, and is expected to report an EPS of $5.05 for the upcoming quarter, a projected growth of 26.88%. Despite a recent stock decline of 1.17%, shares have risen 11.7% since the earnings report, indicating investor confidence. Vertex is actively pursuing regulatory approvals for new therapies, positioning itself for future growth amid ongoing market challenges.
“Vertex Pharmaceuticals Incorporated · was rated · Total Grade · B”
“Vertex Pharmaceuticals Incorporated · was upgraded to · total grade · B”
“Vertex Pharmaceuticals · ended the recent trading session at · $470.10 · -1.17% change from the preceding day's closing price”
“Vertex Pharmaceuticals · had gained · 4.92% · over the past month”
“Vertex Pharmaceuticals · is scheduled to release its earnings on · February 12, 2026”
“Vertex Pharmaceuticals · is forecasted to report an EPS of · $5.05 · showcasing a 26.88% upward movement from the corresponding quarter of the prior year”
“Vertex Pharmaceuticals · is forecasted to report revenue of · $3.16 billion · up 8.66% from the prior-year quarter”
“Vertex Pharmaceuticals · boasts a Zacks Rank of · #3 (Hold)”
“Vertex Pharmaceuticals · is being traded at a Forward P/E ratio of · 23.83”
“Vertex Pharmaceuticals (NASDAQ:VRTX) · reported revenues · amount · $3.08 billion”
“Vertex Pharmaceuticals (NASDAQ:VRTX) · revenue increase · year on year · 11%”
“Vertex Pharmaceuticals (NASDAQ:VRTX) · stock performance · increase · 11.5%”
